Home > News > Natco Pharma recalls breast cancer drug
July 18th, 2009
Natco Pharma recalls breast cancer drug
Abstract:
Natco Pharma Ltd has recalled its breast cancer drug Albupax following an order from the Drug Controller General of India (DCGI), which said that the drug might cause damage to liver.
The Hyderabad-based company has stopped the production, distribution and marketing of the drug and is in the process of recalling stocks, a company spokesperson told Business Line.
"The product has passed all quality tests. However, on DCGI's instructions, we have stopped marketing the product in the interim.
"We are taking immediate steps to investigate the issue," he said.
Testing procedures
The testing procedures for the drug should also be looked into as Albupax was nanotechnology-based products.
"The testing procedures for this drug are quite complex," he added.
Natco is currently engaged in a legal dispute on patent of Albupax with its original innovator, American Biosciences and is awaiting judgment.
Source:
thehindubusinessline.com
Bookmark:
| Related News Press |
News and information
Researchers develop molecular qubits that communicate at telecom frequencies October 3rd, 2025
Next-generation quantum communication October 3rd, 2025
"Nanoreactor" cage uses visible light for catalytic and ultra-selective cross-cycloadditions October 3rd, 2025
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Rice membrane extracts lithium from brines with greater speed, less waste October 3rd, 2025
Researchers develop molecular qubits that communicate at telecom frequencies October 3rd, 2025
Next-generation quantum communication October 3rd, 2025
"Nanoreactor" cage uses visible light for catalytic and ultra-selective cross-cycloadditions October 3rd, 2025
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||